First Capital Advisors Group’s Oncolytics Biotech ONCY Stock Holding History

First Capital Advisors Group’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$520	Buy	+200	New	+$332	﹤0.01%	917

Other funds holding ONCY

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

NDSI

Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return

First Capital Advisors Group's ONCY Position: Q2 2023 in Review

First Capital Advisors Group opened a new position in Oncolytics Biotech (ONCY) in Q2 2023: 200 shares worth $520. The stake represents ﹤0.01% of the portfolio and ranks #917 among its holdings.

32 funds tracked by Wall St. Rank hold ONCY as of Q2 2023.

First Capital Advisors Group held 200 shares of Oncolytics Biotech worth $520 as of Q2 2023.
Oncolytics Biotech was a new First Capital Advisors Group position in Q2 2023.
Oncolytics Biotech made up ﹤0.01% of First Capital Advisors Group's portfolio in Q2 2023, its #917 holding.
32 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2023.

Based on First Capital Advisors Group's 13F filing for Q2 2023, filed 15 Aug 2023.